Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21821171 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2745077 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL6108063 | 0.86 | HSD11B1 (0.33) | CHRNA7HSD11B1 | |
| SCHEMBL6108057 | 0.86 | HSD11B1 (0.33) | CHRNA7HSD11B1 | |
| SCHEMBL6106104 | 0.86 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL6106107 | 0.86 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL6106105 | 0.86 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL1425838 | 0.80 | NR1H2 (0.31) | POLB | |
| SCHEMBL23933653 | 0.79 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2744190 | 0.79 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026050923-A1 | METHOD FOR SYNTHESIZING KEY INTERMEDIATE OF JAK KINASE INHIBITOR | 上海再启生物技术有限公司 | 2026-03-12 | — | — | WO | disclosed |
| CN-118203585-A | Pharmaceutical use of ENPP1 inhibitors | 上海翊石医药科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-112384509-B | Furin inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117642411-A | Small molecule CD73 antagonists and uses thereof | 西藏海思科制药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4282412-A2 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Novartis AG (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3856735-B1 | FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3974420-B1 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | NOVARTIS AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | CADENT THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| CN-114787143-A | ZESTE enhancer homolog 2 inhibitors and uses thereof | 四川海思科制药有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3974420-A1 | N-ALKYLARYL-5-OXYHETEROARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B | Cadent Therapeutics, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| US-8304411-B2 | Dicycloazaalkane derivates, preparation processes and medical uses thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2012-11-06 | — | — | US | disclosed |
| EP-2481739-A1 | DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2010-12-09 | — | — | US | disclosed |
| EP-2246347-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2010-11-03 | — | — | EP | disclosed |
| EP-2133077-A1 | DERIVATIVES OF AZABICYCLO OCTANE, THE METHOD OF MAKING THEM AND THE USES THEREOF AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2009-12-16 | — | — | EP | disclosed |
| US-7135484-B2 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1539733-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | Abbott Laboratories (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ABBOTT LABORATORIES | 2004-03-04 | — | — | US | disclosed |
| WO-2004016604-A2 | AZABICYCLIC COMPOUNDS ARE CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152724-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | CHRNB2 10/4885CHRNB4 13/4885CHRNA3 12/4885 |
| US-20040044029-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHRNA6, CHRNA2 | CHRNB2 10/4885CHRNB4 13/4885CHRNA3 12/4885 |
| US-20230012073-A1 | SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B | GRIN2A, GRIN2C, GRIN3A | CHRNB2 66/4885CHRNB4 82/4885CHRNA3 56/4885 |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | CHRNB2 4299/4885CHRNB4 3608/4885CHRNA3 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.